Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax^TM COVID-19 Vaccine in Japan to Moderna

Takeda Announces Approval of Nuvaxovid^® COVID-19 Vaccine for Primary and Booster Immunization in Japan

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate